



Best-value biological (BVB) medicines / Best-value medicines (BVM) 2022

The HSE-Medicines Management Programme has identified the following biological medicines for which it may initiate a best-value biological (BVB) medicine or best-value medicine (BVM) process in 2022:

- Adalimumab (L04AB04)
- Etanercept (L04AB01)
- Filgrastim (L03AA02)
- Follitropin alfa (G03GA05)
- Pegfilgrastim (L03AA13)
- Teriparatide (H05AA02)